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Aspergillus fumigatus is the most prevalent airborne filamentous fungal pathogen in humans, causing severe and often
fatal invasive infections in immunocompromised patients. Currently available antifungal drugs to treat invasive
aspergillosis have limited modes of action, and few are safe and effective. To identify and prioritize antifungal drug
targets, we have developed a conditional promoter replacement (CPR) strategy using the nitrogen-regulated A.
fumigatus NiiA promoter (pNiiA). The gene essentiality for 35 A. fumigatus genes was directly demonstrated by this
pNiiA-CPR strategy from a set of 54 genes representing broad biological functions whose orthologs are confirmed to be
essential for growth in Candida albicans and Saccharomyces cerevisiae. Extending this approach, we show that the
ERG11 gene family (ERG11A and ERG11B) is essential in A. fumigatus despite neither member being essential
individually. In addition, we demonstrate the pNiiA-CPR strategy is suitable for in vivo phenotypic analyses, as a
number of conditional mutants, including an ERG11 double mutant (erg11BD,p NiiA-ERG11A), failed to establish a
terminal infection in an immunocompromised mouse model of systemic aspergillosis. Collectively, the pNiiA-CPR
strategy enables a rapid and reliable means to directly identify, phenotypically characterize, and facilitate target-based
whole cell assays to screen A. fumigatus essential genes for cognate antifungal inhibitors.
Citation: Hu W, Sillaots S, Lemieux S, Davison J, Kauffman S, et al. (2007) Essential gene identification and drug target prioritization in Aspergillus fumigatus. PLoS Pathog 3(3):
e24. doi:10.1371/journal.ppat.0030024
Introduction
Aspergillus fumigatus is a ubiquitous soil-dwelling sapro-
phytic fungus that propagates through the proliﬁc produc-
tion of air-borne conidia [1]. Large-scale genome
comparisons have shown that no gene sets are shared
exclusively by both Aspergillus fumigatus and any other human
pathogenic fungi sequenced to date, such as Candida or
Cryptococcus species [2]. Thus, it has been recently suggested
that A. fumigatus pathogenesis is based on its saprophytic
lifestyle in combination with the immunosuppressed state of
the host, rather than from genuine fungal virulence factors
[2]. Although A. fumigatus conidia are constantly inhaled and
seldom cause serious medical conditions in healthy individ-
uals, immunocompromised patients (e.g., those with HIV
infection or AIDS, solid organ and bone marrow transplant
recipients, and those receiving chemotherapy) are highly
susceptible to invasive aspergillosis, a fatal systemic infection
[1,3,4]. Current treatment options for invasive aspergillosis
are limited to three classes of antifungal therapeutics:
polyenes (amphotericin B and various liposomal formula-
tions), azoles (e.g., ﬂuconazole, voriconazole, itraconazole),
and, more recently, semisynthetic echinocandins (e.g., caspo-
fungin and anidulafungin) [4,5]. Despite current therapeutic
options, mortality associated with invasive aspergillosis
remains high (ranging from 60% to 90%) and more efﬁca-
cious antifungal drugs with novel mechanisms of action are
needed [4,5].
The identiﬁcation of conserved essential genes required for
the growth of fungal pathogens offers an ideal strategy for
elucidating novel antifungal drug targets. A comprehensive
determination of all the essential genes has been achieved in
the nonpathogenic yeast Saccharomyces cerevisiae [6,7]. Extend-
ing similar genetic approaches to fungal pathogens has
proved difﬁcult due to limited available molecular technol-
ogies and to the asexual nature of most medically relevant
fungi, preventing the use of classical genetics. Nonetheless,
large-scale essential gene identiﬁcation in Candida albicans has
begun through a number of alternative approaches, including
antisense-based gene inactivation [8], transposon-based het-
erozygote screens for hypomorphs [9], homozygote null
mutants [10], and a promoter replacement strategy to
construct conditional mutants [11].
Large-scale functional analysis and essential gene identiﬁca-
tion in A. fumigatus have proved more difﬁcult. Although gene
disruption methodologies have been adapted to A. fumigatus,
they are limited due to the organism’s poor efﬁciency of
homologous recombination as well as the inherent inability to
study essential genes by such means. A. fumigatus essential genes
have been deﬁned using parasexual genetics in which gene
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segregants carrying a gene knock-out [12,13]. Nevertheless,
such an approach is likely unsuitable to systematically identify
all possible essential genes due to irregularities in the para-
sexual cycle of A. fumigatus. Direct demonstration of A. fumigatus
gene essentiality and phenotypic analyses, however, may be
achieved using molecular genetics strategies including RNA
interference or promoter replacement strategies [14,15].
Mouyna et al. (2004) have used RNA interference to produce
the predicted phenotypes associated with both a nonessential
gene involved in melanin biosynthesis (alb1) and an essential
glucan synthase, FKS1 [14]. (Note: In this report, we maintain
gene nomenclature for A. fumigatus genes as previously
described [e.g., alb1 or FKS1]; in cases where previously
uncharacterized A. fumigatus genes are described, standard S.
cerevisiae gene nomenclature and provisional gene names are
adoptedaccordingtotheiryeastortholog.)Todate,conditional
promoter replacement (CPR) strategies applied to A. fumigatus
have been restricted to heterologous promoters including the
Aspergillus nidulans alcA promoter and Escherichia coli tetracy-
cline-regulated promoter [15,16].
Here we report a CPR strategy to identify A. fumigatus
essential genes and to prioritize potential antifungal drug
targets. This strategy uses the A. fumigatus NiiA nitrogen-
regulatable promoter (pNiiA) to delete and replace the
endogenous promoter of selected genes. By applying this
strategy to 54 A. fumigatus genes of diverse biological
functions whose orthologs are known to be essential for
growth in S. cerevisiae and C. albicans, we have identiﬁed 35
genes essential for mycelial growth, with many displaying a
cidal terminal phenotype. We also demonstrate that the
ERG11 gene family is essential in A. fumigatus and that the
resulting pNiiA-CPR strains may be used as cell-based whole
cell assays to examine target-speciﬁc chemical hypersensitiv-
ity. Finally, we show that a number of pNiiA-CPR mutants of
essential genes fail to establish a terminal aspergillosis
infection in a mouse model system. Therefore, both in vitro
and in vivo phenotypic analysis of essential genes may be
performed. This initial gene set comprises an experimentally
validated drug target set that is broadly conserved within
fungal pathogens and therefore of signiﬁcant relevance to
antifungal drug discovery.
Results
Construction of A. fumigatus Conditional Mutant by
Promoter Replacement
A. fumigatus conditional mutants were constructed by CPR
using pNiiA.p NiiA was chosen based on previous work in
both A. fumigatus and A. nidulans demonstrating its tight
nitrogen-dependent transcriptional regulation [17,18]. Two
operationally independent signals control pNiiA expression:
an inducer (e.g., nitrate or other secondary nitrogen source)
and a repressor (e.g., ammonium or other primary nitrogen
source). Expression is achieved solely in the absence of
ammonium and the presence of nitrate; however, repression
is achieved by the presence of ammonium regardless of the
presence of other nitrogen [17,18]. pNiiA-CPR mutants were
constructed by homologous recombination-mediated dele-
tion of the endogenous promoter (approximately 250 base
pairs of promoter sequence immediately preceding the start
codon of the gene) and replacement with an NiiA promoter
cassette marked with the pyrG selectable marker (Figure 1A
and 1B; see Materials and Methods for details). To test the
pNiiA-CPR strategy, TUB1 and MET2 were ﬁrst selected.
TUB1 encodes the broadly conserved and essential protein a-
tubulin, and MET2 encodes a homoserine O-acetyltransferase
involved in methionine biosynthesis, mutations of which
cause methionine auxotrophy. TUB1 and MET2 pNiiA-CPR
mutants displayed wild-type mycelial growth on inducing
medium (Aspergillus minimal medium [AMM] plus nitrate),
but neither mutant was able to grow on repressing medium
(AMM plus ammonium, Figure 1C). Furthermore, the A.
fumigatus MET2 conditional mutant displayed a tight methio-
nine auxotrophy that was fully suppressed by methionine
added to the medium (Figure 2A). pNiiA-CPR conditional
mutants of GFA1 and ALR1, whose orthologs are essential in
both S. cerevisiae and C. albicans, were also examined (Figure
1C). GFA1, a glutamine-fructose-6-phosphate aminotransfer-
ase catalyzing the ﬁrst step in the chitin biosynthesis pathway,
was shown to be essential in A. fumigatus. However, CPR
mutants of ALR1 (a metal cation transporter belonging to a
gene family in A. fumigatus) failed to display any growth defect
under repressing conditions, revealing that ALR1 is non-
essential in A. fumigatus (see below).
According to the severity of the growth phenotype
displayed by CPR mutants in repressing conditions, qualita-
tive scores were assigned to each of the CPR mutants to
classify the terminal phenotype (Figure 1D). A 4þ shutoff
phenotype was assigned to those strains (e.g., GFA1) that
completely fail to grow on repressing medium after 48 h at 30
8C. Similarly, a 3.5þor 3þshutoff phenotype was used to score
those strains that showed a very severe (e.g., PFS2) or a severe
(e.g., ALG7) growth phenotype, respectively. Other growth
defects were scored as 2þ(mild), 1þ(minor; e.g., CDC24), or 0þ
(no defect; e.g., ALR1). All essential genes described here
showed either a complete absence of growth (4þ)or a dramatic
growth defect (3.5þ and 3þ) under repressing conditions.
Evaluating pNiiA-CPR Reliability by Genetic Approaches
To test its reliability, the pNiiA-CPR strategy was further
applied to multiple A. fumigatus genes whose null phenotype
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Author Summary
Aspergillus fumigatus is an opportunistic filamentous fungal
pathogen of emerging clinical significance. Although virulence
factors are seen as potential drug targets, neither genetic analyses
nor genomic comparisons have identified genuine virulence factors
in A. fumigatus. Essential genes required for fungal growth and
viability also serve as potential drug targets, yet few have been
described in this pathogen. To begin to catalog essential genes in A.
fumigatus, we devised a genetic strategy for creating conditional
mutants by promoter replacement of target genes using a nitrogen-
regulated promoter. Applying this genetic approach to A. fumigatus
genes orthologous to known essential genes of the nonpathogenic
yeast, Saccharomyces cerevisiae and Candida albicans, we demon-
strate a robust enrichment for identifying essential genes conserved
within this pathogen. We show that A. fumigatus conditional
mutants can be evaluated according to their terminal phenotypes
(e.g., conidial germination, growth, morphology, and cidal versus
static consequences) and pathogenesis in a murine model of
systemic aspergillosis to prioritize essential genes as novel drug
targets suitable for developing broad-spectrum antifungal agents.was either known or independently veriﬁed by other means.
First, pNiiA-CPR mutants were constructed for ﬁve genes
(HIS3, TRP5, MET16, LYS9, and LYS4) involved in amino acid
biosynthesis. Growth was completely impaired for all strains
under repressing conditions lacking amino acids but fully
restored when the cognate amino acid was provided (Figure
2A). Second, pNiiA-CPR mutants were constructed for four
genes (FKS1, GUS1, SPE2, and HEM1) whose essentiality in A.
fumigatus has been demonstrated by a parasexual genetic
strategy [12,13]. In each instance, the conditional mutant
displayed an essential growth phenotype (Figure 2B). Third,
we constructed pNiiA-CPR mutants of two nonessential genes
(ayg1 and arp2) involved in conidial pigmentation whose null
phenotypes result in the production of yellow-green and
pink-red conidiospores, respectively [19]. Hence, conidial
pigmentation phenotypes of ayg1 and arp2 mutants serve as
whole cell reporters to monitor the level of repression
achieved by the pNiiA-CPR system. Indeed, pNiiA-ayg1 and
pNiiA-arp2 conidia color shifted from dark-green (wild-type
conidia color) under inducing conditions to yellow-green
(ayg1) or red-pink (arp2) under repressing conditions (Figure
2C). Finally, we applied this pNiiA-CPR strategy to A. fumigatus
nudC, a gene shown to be essential by promoter replacement
with A. nidulans alcA promoter [15]. Consistent with a previous
report [15], the pNiiA-nudC mutant displayed (1) an essential
growth phenotype (Figure 2D), (2) a germination defect of
conidia with approximately 70% of conidia failing to
germinate and approximately 30% of conidia forming short
growth-arrested germ tubes (Figure S1), and (3) an nudC
Figure 2. Genetic Evaluation of the pNiiA-CPR Strategy
(A) Phenotypes of pNiiA-CPR mutants for HIS3, TRP5, MET16, MET2, LYS9,
and LYS4. Under standard repressing conditions (Re, AMM plus
ammonium), all strains lacked detectable growth (4þ phenotype).
Growth was unimpaired under inducing conditions (In; AMM plus
nitrate). Growth phenotypes of pNiiA-CPR mutants under repressing
conditions were specifically suppressed if the cognate amino acid was
provided to the growth media (His, histidine; Trp, tryptophan; Met,
methionine; or Lys, lysine).
(B) Growth phenotypes of pNiiA-CPR mutants for the previously reported
A. fumigatus essential genes, FKS1, GUS1, SPE2, and HEM15 [12,13].
Reproducible 4þ essential growth phenotypes are observed for each
pNiiA-CPR mutant under repressing conditions with the exception of
FKS1, which produced a 3.5þ growth phenotype.
(C) arp2 and ayg1 conidial color phenotypes by the pNiiA-CPR strategy.
Wild-type (WT) strain CEA10, pNiiA-arp2, and pNiiA-ayg1 mutants display
normal dark-green conidia color under inducing conditions. Gene-
specific conidia color phenotypes characteristic of their known null
phenotype [19] are specifically detected under repressing conditions.
(D) nudC growth phenotype by the pNiiA-CPR strategy. Highly
reproducible growth and morphological phenotypes associated with
nudC mutants are observed (see Figure S1) as similarly determined using
an alcA heterologous conditional promoter [15].
doi:10.1371/journal.ppat.0030024.g002
Figure 1. Outline of the A. fumigatus pNiiA-CPR Strategy
(A) A cloning vector, pPyrG-pNiiA, was created specifically for the
construction of CPR cassettes. This plasmid contains an A. niger pyrG
(encoding orotidine-59-phosphate decarboxylase and required for
uridine-uracil prototrophy) as a selection marker [41], as well as an
Amp
þselection marker and the A. fumigatus pNiiA conditional promoter.
Unique restriction sites have been engineered at either side of the pyrG-
pNiiA cassette to facilitate subcloning of flanking sequences.
(B) Schematic overview of the pNiiA-CPR strategy and strain confirmation
by PCR genotyping. Promoter replacement cassettes were constructed
by inserting approximately 1.5 kb of homologous flanking sequences of
the target gene (L-arm and R-arm) into the Not1/Mlu1 and Asc1/Pac1
restriction sites, respectively. After Not1 and Pac1 double digestion, the
linearized pNiiA-CPR cassette was introduced into CEA17 strain (pyrG
 )
by protoplast transformation. As indicated, three sets of primers were
used to perform genotypic PCRs to map the expected promoter
replacement junctions (L1/L2 for left-arm junction, R1/R2 for right-arm
junction) and to confirm the deletion of the native promoter (L1/P).
(C) Phenotype of transformants obtained by the pNiiA-CPR strategy for
MET2, TUB1, GFA1, and ALR1. CPR mutants were examined under pNiiA-
inducing (AMM plus nitrate) and repressing (AMM plus ammonium)
conditions after 36 h at 30 8C.
(D) Growth phenotypes of GFA1, PFS2, ALG7, CDC24, and ALR1 pNiiA-CPR
mutants under these standard repressing conditions are scored
qualitatively as the following: 4þ, essential for cell viability, no growth
under repressing conditions; 3.5þ or 3þ, showing very strong or strong
growth defect; 2þor 1þ, mild to minor growth defect; and 0þ, no growth
phenotype observed.
doi:10.1371/journal.ppat.0030024.g001
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A. fumigatus Essential Genenuclear distribution terminal phenotype characterized by
multinucleate conidia (Figure S1).
An advantage to the use of large homologous ﬂanking
sequences to pNiiA-CPR cassettes is that multiple independ-
ent promoter replacement mutants could be recovered for a
given gene. Thus, gene essentiality can be independently
validated from multiple pNiiA-CPR mutants. Indeed, multiple
independent pNiiA-CPR mutants (n . 2) were recovered for
18 of the 19 genes mentioned above, and in all cases, their
independent pNiiA-CPR mutants displayed reproducible
growth phenotypes under repressing conditions. Although
the essential growth phenotype of GUS1 was based on the
single pNiiA-GUS1 mutant recovered, its essentiality is
consistent with previous work and with its predicted function
as a glutamate-tRNA sythetase [13].
Direct Comparison between pNiiA-CPR and Gene
Disruption Terminal Phenotypes
Reliability of the pNiiA-CPR system was also assessed bypyrG-
based gene disruption of multiple genes shown to be essential
by the pNiiA-CPR approach (Table 1). In fact, viable null
mutants of ERG11A, ERG11B, ERG27, ROM2, and MET2 (when
exogenous methionine was provided) were recovered, consis-
tent with their nonessential orconditional essential phenotypes
determined by pNiiA-CPR mutants. Moreover, no viable null
mutants were recovered for either TOM40 or LUC7 by gene
disruption (two essential genes identiﬁed by the pNiiA-CPR
approach) despite a signiﬁcantly large number of transform-
ants examined (84 for TOM40 and 107 for LUC7, respectively)
(Table1). Thus,theessentialityofTOM40 andLUC7isshown by
both the pNiiA-CPR strategy and gene deletion analysis.
Collectively, these data demonstrate that robust genetic
conclusions spanning an extensive set of ‘‘phenotypic reporter
genes’’ are reliably reproduced by the pNiiA-CPR strategy.
Quantitative Analysis of pNiiA-CPR Transcriptional
Regulation
Reverse transcription (RT)-PCR was ﬁrst performed to
monitor pNiiA-CPR gene expression levels for all previously
described genes in Table 1. As pNiiA-MET2 mutants grow
normally in repressing media supplemented with methionine,
MET2 mRNA expression could be assessed in both inducing
and pNiiA-repressing conditions by RT-PCR. MET2 mRNA
was detected in both the pNiiA-MET2 mutant and wild-type
CEA10 on inducing medium; however, no MET2 transcript
was detected in the pNiiA-MET2 mutant on repressing
medium supplemented with methionine (Figure 3A). Sim-
ilarly, mRNA transcripts were detected by RT-PCR in CEA10
and pNiiA-CPR mutants for ERG11A, ERG11B, ERG27, ALR1,
and ROM2 under inducing conditions but not from pNiiA-
CPR mutants maintained under repressing conditions (Figure
S2). In addition, Northern blot analysis also conﬁrmed a
signiﬁcant depletion of ALR1 mRNA levels under repressing
Table 1. Comparison of Growth Phenotypes Observed by pNiiA-
CPR Methods versus Gene Knockout
A. fumigatus
Gene
Growth
Phenotype
of pNiiA-CPR
Mutant
a
Number of Viable
Null Mutants
Recovered
b
Reproducible
Growth
Phenotype
ERG11A 0þ 4/23
c Yes, viable
ERG11B 0þ 2/23 Yes, viable
ERG27 0þ 1/12 Yes, viable
ROM2 0þ 1/15 Yes, viable
LUC7 4þ 0/107 Yes, essential
TOM40 4þ 0/84 Yes, essential
MET2 4þ 3/24
d Yes, auxotroph
aPhenotypes were examined under standard pNiiA-repressing conditions, and qualitative
shutoff phenotype is shown.
bDemonstrated viability or inferred essentiality of null phenotype is shown.
cNumber of viable null mutants identified versus the number of transformants screened
by PCR genotyping (e.g., 4/23 reflects four confirmed, viable null mutants obtained
among 23 transformants examined).
dViable deletion mutants identified by plating onto methionine-supplemented medium.
doi:10.1371/journal.ppat.0030024.t001
Figure 3. Expressional Level Analysis of pNiiA-CPR Mutants
(A) RT-PCR of pNiiA-MET2: (a) pNiiA-MET2 mutant under inducing
conditions, (b) pNiiA-MET2 mutant under repressing conditions plus
100 lg/ml methionine, (c) pNiiA-MET2 mutant under inducing condition
plus 100 lg/ml methionine, and (d) wild-type A. fumigatus strain (CEA10)
under repressing conditions. To monitor and ensure even sample
loading, RT-PCRs for the ACT1 transcript were also performed using
identical samples. In addition, standard PCR was performed to confirm
that there is no detectable genomic-DNA contamination.
(B) Northern blot analysis of pNiiA-ALR1 mutant expression levels.
Northern blot was performed with RNA samples prepared from the
nonessential ALR1 mutant and wild-type cells growing in standard
inducing (In) or repressing (Re) conditions. ACT1 transcript levels served
as sample loading controls.
(C) Real-time RT-PCR analysis of expression level of pNiiA-ALR1 and pNiiA-
MET2.p NiiA-CPR mutants and wild-type strain (CEA10) were grown in
inducing (In) or repressing (Re) medium at 37 8C for 20 h, and total RNA
was extracted from identical time points. The relative expression level
normalized to total input RNA [43] is displayed on the y-axis. Error bars
represent SD. Compared to wild-type, the relative expression level for
ALR1 and MET2 is 0.013 and 0.061 under repressing conditions and 2.49
and 23.58 under inducing conditions, respectively.
(D) pNiiA-TUB1 expression level under inducing (In) and repressing (Re)
conditions versus wild-type level is displayed on the y-axis. Error bar
represents SD. The relative expression level of pNiiA-TUB1 versus wild-
type is 0.06 under repressing conditions and 6.35 under inducing
conditions, respectively. Note: Since real-time RT-PCR was performed
using primers detecting both pNiiA-TUB1 and wild-type allele, data
shown were calculated by subtracting wild-type level from total inducing
(In) and total repressing (Re) level, respectively.
doi:10.1371/journal.ppat.0030024.g003
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A. fumigatus Essential Geneconditions (despite the lack of a clear growth phenotype)
versus its endogenous level of expression in wild-type CEA10
(Figure 3B). Although the ALR1 mRNA levels of the ALR1
conditional mutant were clearly elevated compared to the
wild-type, no deleterious growth phenotype was detected
(Figure 1C).
Real-time RT-PCR was performed to further evaluate the
achievable range of expression levels for three pNiiA-CPR
mutants shown to yield either a nonessential (ALR1), a
conditional essential (MET2), or an essential (TUB1) terminal
phenotype (Figure 3C and 3D). Compared to wild-type, ALR1
and MET2 expression levels in CPR mutants were dramati-
cally reduced by 75.9-fold and 16.3-fold under repressing
conditions and elevated by 2.8-fold and 23.6-fold under
inducing conditions, respectively (Figure 3C). To overcome
the technical difﬁculty of performing real-time RT-PCR on
an essential gene, a TUB1 tandem duplication mutant was
constructed in which the pNiiA-TUB1 allele is balanced by a
wild-type TUB1 copy under the control of its native
promoter. Thus, expression of the pNiiA-regulated TUB1
allele could be monitored under repressing conditions (see
Materials and Methods). Real-time RT-PCR performed with
this strain revealed expression of the pNiiA-TUB1 allele to be
approximately 0.06-fold when repressed and 6.3-fold under
inducing conditions relative to normal TUB1 expression
levels (Figure 3D). Collectively, these data demonstrate that
the pNiiA-CPR strategy typically achieves tight regulatable
expression and suggest that it could be reliably applied to
large-scale analysis of gene essentiality in A. fumigatus.
Large-Scale Identification of Essential Genes
The genomic sequence of A. fumigatus strain AF293 [20], as
well as a second clinical isolate used in this study, CEA10,
where approximately 103 coverage has been obtained (N.
Fedorova, V. Joardar, J. Crabtree, M. Anderson, R. Maiti, et al.,
unpublished data), provides an opportunity to systematically
identify essential genes. Although global annotation of the A.
fumigatus genome is ongoing, homologs to genes of interest
were identiﬁed through search alignment tools and corre-
sponding promoter replacement cassettes designed accord-
ingly. In total, 54 A. fumigatus genes were selected for pNiiA-
CPR analysis, of which 49 are known to be essential (or
conditionally essential) for growth in S. cerevisiae with all but
three of these being essential for normal growth in C. albicans
(Table 2). In addition, genes were selected so as to represent a
broad diversity of gene functions and cellular processes.
Biasing this A. fumigatus gene set toward those essential in
both S. cerevisiae and C. albicans builds on previous work
demonstrating that at least 60% of C. albicans genes
homologous with essential S. cerevisiae genes were also
essential in C. albicans [11]. Therefore, we reasoned that a
set of genes experimentally demonstrated as essential in two
distinct hemiascomycetes would be highly enriched for genes
sharing conserved essential functions within the euascomy-
cetes.
Analysis of this A. fumigatus gene set revealed 35 genes
displaying a 3þ or greater (3.5þ or 4þ) essential growth
phenotype (Table 2). Excluding genes involved in amino acid
biosynthesis, no signiﬁcant differences in terminal growth
phenotypes were observed between minimum medium
(AMM) and rich medium (Aspergillus complete medium
[ACM]). Essential genes comprise a spectrum of biological
functions including lipid, ergosterol, cell wall, amino acid,
protein, and heme biosynthesis, as well as glycosylation,
secretion, RNA processing, and novel genes of unknown
functions (Table 2). Moreover, among those genes displaying
an essential phenotype in both S. cerevisiae and C. albicans and
predicted to have only a single ortholog in A. fumigatus (n ¼
44), 32 genes (73%) are experimentally demonstrated as
sharing a conserved growth phenotype of 3þ or greater in A.
fumigatus.
Essential genes identiﬁed in this manner constitute a
collection of possible antifungal drug targets, and micro-
scopic examination of their terminal growth phenotypes may
assist in their prioritization (Figure 4). For example,
repression of GFA1 produced enlarged and highly disrupted
nongerminating conidia that failed to undergo any polarized
growth. As GFA1 is predicted to encode the sole glutamine-
fructose-6-phosphate aminotransferase activity responsible
for the ﬁrst and rate-limiting step in chitin synthesis, this
terminal phenotype likely reﬂects the normal interdepend-
ence between cell wall biosynthesis and polarized growth.
Conidia of SEC31 and SLY1 incubated under repressing
conditions were unable to germinate, suggesting that these
genes are required for the initiation of germ tubes, whereas
terminal phenotypes of TUB1, ERG10, and, most promi-
nently, PRI1, resulted in growth-arrested germ tubes. Inter-
esting, HEM15 displayed a more complex terminal phenotype
of dramatically swollen conidia with single or multiple germ
tubes. Repression of pNiiA-FKS1 yielded stubby and highly
branched micromycelial germlings that morphologically
resemble the chemotype observed when A. fumigatus is treated
with Fks1p-speciﬁc inhibitors such as caspofungin and
related echinocandins [21]. Thus, distinct terminal pheno-
types are identiﬁed among pNiiA-CPR mutants, and in some
instances, they appear more severe than that caused by either
genetic or chemical inactivation of FKS1.
Essential genes with a cidal terminal phenotype are
commonly preferred since genetic evidence predicts that
chemical inhibitors of such targets may display similar
chemotypes. An assay to evaluate cidal or static terminal
phenotypes was applied to essential genes displaying a 3.5þor
4þ growth phenotype (Table 2) by incubating conidia in
pNiiA-repressing medium for various durations of time
before washing and plating conidia onto pNiiA-inducing
medium where viability was scored by counting colony-
forming units (CFU) (see Materials and Methods and Figure
5). Of 28 genes tested, six genes (approximately 21%),
including GFA1 (Figure 5), displayed a cidal terminal
phenotype, as scored by a signiﬁcant reduction (greater than
90%) of CFU after 24-h incubation in repressing medium.
Additional genes demonstrating a cidal terminal phenotype
include KRR1, SEC31, SLY1, TUB1, and GUS1 (Table 2).
Additional genes displayed a slow cidal phenotype, as scored
by signiﬁcant reduction (greater than 90%) in CFU after 48-
or 72-h incubation in repressing medium, or a static terminal
phenotype after 48-h incubation in repressing conditions as
shown with TRR1 (Figure 5, Table 2).
The ERG11 Gene Family Is Essential in A. fumigatus
Identifying gene families that are essential for the growth
and viability of A. fumigatus can be missed by our approach
and thus require additional considerations. For example,
duplicate ERG11 genes (encoding 14a-demethylase, the
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A. fumigatus Essential Geneknown target of azole-based antifungal agents) exist in A.
fumigatus [22,23]. While disruption of ERG11A displays no
effect on growth or ergosterol levels [23], it remained
unknown whether ERG11B alone or the gene pair together
is essential in A. fumigatus. To address this, individual pNiiA-
CPR mutants of ERG11A and ERG11B were constructed, with
neither producing a noticeable growth defect under repres-
sing conditions (Figure 6, Table 1). Further, viable erg11AD
and erg11BD null mutants displaying robust growth were
readily recovered (Figure 6, Table 1). Thus, these data
demonstrate that neither member of the ERG11 gene family
is essential individually in A. fumigatus. To examine whether
the ERG11 gene family is essential, a double mutant was
constructed by creating a pNiiA-ERG11A allele within an
Figure 4. Analysis of pNiiA-CPR Associated Morphological Terminal Phenotypes
Terminal growth phenotypes of pNiiA-CPR mutants were observed under a microscope (3160) with conidia grown for 36 to 40 h at 30 8C under
standard repressing conditions. A continuum of conidia germination phenotypes of high penetrance was observed; ranging from those completely
failing to undergo polarized growth (SEC31, SLY1) or swollen and highly disorganized condidia (GFA1), to those displaying stunted (TUB1, ERG10) or
nonbranching germlings with swollen conidia (HEM15) with only rudimentary polarized growth. Micromycelial colonies were observed for a pNiiA-FKS1
mutant and resembling the morphology of wild-type A. fumigatus when grown in the presence of minimum effective concentration (MEC) of the FKS1p
inhibitor, caspofungin [21]. Growth phenotypes under inducing conditions are shown in Figure S3.
doi:10.1371/journal.ppat.0030024.g004
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A. fumigatus Essential GeneERG11B null mutant background (see Materials and Meth-
ods). The resulting ERG11 double mutant (erg11BD,p NiiA-
ERG11A) displays robust growth under the inducing con-
dition, with no growth evident under repressing conditions
(Figure 6). Therefore, these data suggest that either of the
ERG11 gene pair can functionally compensate for loss of the
other, and the genetic inactivation of both ERG11A and
ERG11B indicates their essentiality in A. fumigatus.
In Vivo Analysis of pNiiA-CPR Mutants in a Murine Model
of Systemic Aspergillosis
Animal models of fungal pathogenesis provide important
experimental veriﬁcation whether genetic mutations abro-
gate (or attenuate) the virulence of the pathogen. As mouse
serum contains approximately 200 lM ammonium [24] and
such levels of ammonium are theoretically sufﬁcient to
repress the pNiiA promoter, we tested this by streaking
pNiiA-CPR mutants onto AMM plates containing 20% mouse
serum (Figure 7A). In each case, TUB1, SEC31, GCD6, GFA1,
MET2, AUR1, and pNiiA-ERG11A, erg11BD CPR mutants
reproduced their terminal growth phenotypes as observed
on either AMM or rich medium (Table 2), demonstrating that
mouse serum levels of ammonium (or other primary nitrogen
source) are sufﬁcient to repress the NiiA promoter. Indeed, as
even higher ammonium levels (approximately 1 to 4 mM) of
repressor exist in mouse tissues (e.g., liver, kidney, brain,
muscle) [24], we reasoned that the virulence of pNiiA-CPR
mutants could be examined in a murine model of aspergil-
Figure 5. Determination of Cidal or Static Terminal Phenotypes
A representative example of cidal and static terminal phenotypes for
GFA1 and TRR1 pNiiA-CPR mutants is shown.
(A) pNiiA-GFA1 displayed a cidal terminal phenotype as a dramatic
(greater than 90%) reduction in CFU was observed after incubation in
pNiiA-repressing conditions for 24 or 48 h.
(B) pNiiA-TRR1 revealed a static terminal phenotype as no significant
reduction in CFU counts was detected after 48-h incubation under
repressing conditions. A summary of all additional cidal/static terminal
phenotypes for A. fumigatus genes displaying 4þ qualitative growth
phenotypes is provided (see Table 2).
doi:10.1371/journal.ppat.0030024.g005
Figure 6. Phenotypic Analyses of ERG11 Gene Family
Growth phenotypes of ERG11 gene family were observed with pNiiA-CPR
mutants, null deletion mutants, and double mutants (erg11BD,p NiiA-
ERG11A). Strains were grown on either inducing medium (AMM plus
nitrate) or repressing medium (AMM plus ammonium) at 30 8C for 40 h.
doi:10.1371/journal.ppat.0030024.g006
Figure 7. In Vivo Validation of A. fumigatus pNiiA-CPR Mutants in an
Immunocompromised Murine Model of Systemic Infection
(A) pNiiA-CPR mutants growing on AMM plus 20% mouse serum (Sigma)
reproduced their terminal growth phenotypes as observed on either
AMM plus ammonium or rich medium (Table 2).
(B and C) In vivo validation of pNiiA-CPR mutants. (B) ICR male mice were
immunocompromised by administration of cyclophosphamide at 150
mg/kg twice prior to infection and 100 mg/kg twice a week after
infection. Approximately 10
5 viable conidia from individual pNiiA-CPR
mutants (TUB1, SEC31, GCD6, GFA1, MET2, and AUR1) were injected into
the tail vein of immunocompromised mice (five mice per group). Signs of
infection were monitored for up to 12 d following infection. Wild-type
strain CEA10 and the starting strain CEA17 (a pyrG
  auxotroph of CEA10)
[25,39] were included as positive controls for virulence and avirulence,
respectively.
(C) Genetic inactivation of the ERG11 gene family promotes avirulence in
an immunocompromised murine model of systemic infection. Patho-
genesis of erg11AD, erg11BD, and an ERG11 double mutant (erg11BD,
pNiiA-ERG11A) was similarly analyzed (as described above) but over a
longer postinfection period (22 d), and animal survival was compared to
CEA10 and CEA17 control strains.
doi:10.1371/journal.ppat.0030024.g007
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A. fumigatus Essential Genelosis. To test this, an animal model was ﬁrst established using
mice that were immunocompromised by cyclophosphamide
and infected with 100,000 conidia by tail vein injection (see
Materials and Methods). Control experiments demonstrate
that all mice (n¼5) infected with the wild-type virulent strain,
CEA10, died from infection within 8 d, while 100% survival
was observed for mice (n¼5) infected with a known avirulent
strain, CEA17 [25]. Virulence of CPR mutants of TUB1,
SEC31, GCD6, GFA1, AUR1, and MET2 was similarly examined
(Figure 7B). No mortality or morbidity was observed for mice
infected with pNiiA-TUB1 over the 12-d period, as predicted
for a core essential gene that is signiﬁcantly repressed and for
which sufﬁcient in vivo ammonium levels exist. Similarly,
pNiiA-based repression was sufﬁcient to fully abrogate
virulence of SEC31, GFA1, and GCD6 (Figure 7B). Further,
whereas both erg11AD and erg11BD mutants were similarly
virulent as the wild-type CEA10, an ERG11 double mutant
(erg11BD,p NiiA-ERG11A) was fully avirulent over an extended
22-d period (Figure 7C). On the other hand, attempted
repression of MET2 and AUR1 had no effect on A. fumigatus
virulence (Figure 7B). As pNiiA-MET2 growth was unaffected
by serum, and a C. albicans MET2 tetracycline-regulatable
conditional mutant is similarly virulent [10], this likely
reﬂects that sufﬁcient levels of methionine are scavenged to
support growth both in vitro and in vivo. Although the
observed virulence phenotype of pNiiA-AUR1 remains
unclear (see Discussion), we demonstrate that pNiiA-CPR
mutants generally gave in vivo phenotypes consistent with
reliable repression being achieved.
Chemical Hypersensitivity of pNiiA-CPR Mutants
In principle, partially depleting the activity of a particular
gene product sensitizes cells to compounds that act through
that target. Modulating gene dosage may be achieved by
deleting one copy in a diploid organism [6,26], antisense
interference [8], or reduced gene expression through titrat-
able repression of a regulatable promoter [11]. To test
whether intermediate expression levels of pNiiA-CPR mu-
tants could be achieved to produce chemical hypersensitivity,
we ﬁrst examined the chemical sensitivity of a pNiiA-ALG7
mutant to its cognate inhibitor, tunicamycin. A partial
depletion of Alg7p was inferred by growing pNiiA-ALG7 in
the presence of an ammonium/nitrate ratio sufﬁcient to
reduce growth rate by approximately 50%. Under such
conditions, depletion of Alg7p resulted in an 8- to 16-fold
shift in minimum inhibitory concentrations (MICs) to
tunicamycin without any signiﬁcant change in sensitivity to
either ﬂuconazole or itraconazole (Table 3). Moreover, no
signiﬁcant change in tunicamycin MIC was observed across a
panel of similarly sensitized pNiiA-CPR mutants (Table 3).
Therefore, partial depletion of the A. fumigatus Alg7p resulted
in a speciﬁc hypersensitivity to tunicamycin.
A. fumigatus exhibits an extremely low susceptibility to
ﬂuconazole (MIC . 256 lg/ml), a feature attributed to the
genetic redundancy of ERG11 in this pathogen [22,23]. Using
the conditional mutants, we tested whether inactivation of
either member of the ERG11 gene family may sensitize A.
fumigatus to ERG11-speciﬁc inhibitors (Table 3). As neither
ERG11 gene displays growth defects under full repressing
conditions, pNiiA-CPR mutants of ERG11A and ERG11B serve
as whole cell assays by growing each mutant under full
repressing conditions and determining their respective MIC
to ﬂuconazole. Indeed, the pNiiA-ERG11A mutant displayed
an 8- to 16-fold lower MIC to ﬂuconazole; no detectable drug
hypersensitivity was observed for either pNiiA-ERG11B or
control strains tested (Table 3). MIC determinations using
null mutants of erg11AD and erg11BD independently con-
ﬁrmed that depletion of ERG11A (rather than ERG11B)
similarly sensitizes A. fumigatus 8- to 16-fold to ﬂuconazole.
Moreover, only depletion of ERG11A, as either a pNiiA-CPR
mutant or null mutant, produced hypersensitivity to itraco-
nazole, another triazole that, unlike ﬂuconazole, displays
strong activity against wild-type A. fumigatus (Table 3). Neither
pNiiA-CPR mutants nor null mutants of ERG11A or ERG11B
displayed a change in MIC to tunicamycin. This preferential
drug sensitivity of mutants depleted of A. fumigatus ERG11A
further supports the feasibility of target-based sensitized
whole cell assays using pNiiA-CPR mutants. These data also
suggest ERG11A likely encodes the major 14a-demethylase
activity and that ERG11A, rather than ERG11B, largely
contributes to the poor susceptibility of A. fumigatus to
ﬂuconazole (see Discussion).
Discussion
In this report, we describe a pNiiA-CPR strategy to
construct A. fumigatus conditional mutants and to directly
identify and evaluate gene essentiality in vitro and in vivo.
Replacement of the endogenous gene promoter with pNiiA
typically enables a robust shutoff of gene expression to assess
terminal growth phenotypes including intracellular, morpho-
logical, and cidal growth consequences. Collectively, the
completion of the A. fumigatus genomic sequence, an under-
standing of essential genes in other yeasts, and the pNiiA-CPR
strategy enable a rational approach to determine the
essentiality of orthologous genes in A. fumigatus. Indeed,
genomic comparisons between A. fumigatus and other
eukaryotes reveals that, in all but one of 131 largely essential
eukaryote orthologous groups, an A. fumigatus ortholog is
identiﬁed [27]. Here we demonstrate that at least 73% of the
predicted essential genes we examined were essential for
Table 3. MIC of Antifungal Drugs to pNiiA-CPR Strains
A. fumigatus Strain Fluconazole
a Itraconazole Tunicamycin
pNiiA-ERG11A, induced .100 0.6 .128
pNiiA-ERG11A, repressed
b 6.25 to 12.5 0.037 to 0.075 .128
pNiiA-ERG11B, induced .100 0.6 .128
pNiiA-ERG11B, repressed .100 0.6 .128
erg11AD 6.25 to 12.5 0.037 to 0.075 .128
erg11BD .100 0.6 .128
pNiiA-ALR1, induced .100 0.6 .128
pNiiA-ALR1, repressed .100 0.6 .128
pNiiA-ALG7, induced .100 0.6 .128
pNiiA-ALG7, repressed
c .100 0.6 8.0 to 16.0
pNiiA-SPE2, induced .100 0.6 .128
pNiiA-SPE2, repressed .100 0.6 .128
CEA10 (wild-type) .100 0.6 .128
aAll MIC values are given as lg/ml.
bTo repress ERG11A, ERG11B, and ALR1 pNiiA-CPR mutants, strains were assayed in AMM
containing 10 mM ammonium.
cTo repress ALG7 and SPE2 pNiiA-CPR mutants, strains were assayed in AMM containing 5
mM ammonium and 5 mM nitrate.
doi:10.1371/journal.ppat.0030024.t003
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A. fumigatus Essential Genegrowth. Hence, a broad spectrum of antifungal targets
conserved within major human fungal pathogens was
efﬁciently identiﬁed. We also demonstrate how this approach
can be extended to gene families (e.g., ERG11) and that the
resulting pNiiA-CPR mutants serve as target-based whole cell
assays suitable for drug screening.
To evaluate the utility of the NiiA conditional promoter for
studying gene essentiality, an extensive analysis of its
regulatable expression was performed. First, its reliability
was examined by genetic means. Conditional mutants of
multiple genes encoding functions involved in amino acid
biosynthesis were constructed, and all showed 4þ shutoff
growth phenotypes that could be reversed by adding back
appropriate amino acids to the medium (Figure 2A, Table 2).
In addition, A. fumigatus genes examined by the pNiiA-CPR
strategy and independently examined by a parasexual
genetics strategy [12,13] yielded reproducible essential
growth phenotypes (Figure 2B). pNiiA-CPR mutants of genes
in the melanin biosynthetic pathway also gave the predicted
terminal conidia color change characteristic to their known
null phenotype (Figure 2C) [19]. Thus, genetic data strongly
suggest that sufﬁciently achievable repression levels are
obtained by the pNiiA promoter independent of the gene
to which it is linked or its physical location within the
genome. We also directly compared terminal phenotypes of
A. fumigatus nudC genes achieved by pNiiA-CPR strategy to
that achieved by the alcA conditional promoter system [15]
and obtained highly comparable nudC terminal phenotypes
resembling its reported null phenotype (Figures 2D and S1).
Finally, a comparative analysis was performed of terminal
phenotypes for seven genes evaluated by both pNiiA-CPR and
gene disruption strategies. By both methods, three genes
(LUC7, TOM40, and MET2) were shown to be essential, while
four genes (ERG11A, ERG11B, ERG27, and ROM2) were found
to be nonessential (Table 1).
Genetic interrogation of the pNiiA-CPR strategy supports a
general reliability of this method, but quantitative metrics for
expression levels achieved by the NiiA promoter were also
required. Multiple genes monitored by RT-PCR displayed
repression levels noticeably below wild-type expression levels
(Figure 3A; also see Figure S2). Further, real-time RT-PCR
analysis of expression levels among pNiiA-CPR mutants for
ALR1, MET2, and TUB1 demonstrates achievable repression
levels in the range of approximately 16- to 76-fold below wild-
type (Figure 3C and 3D). In several cases, overexpression was
detected by RT-PCR and/or real-time RT-PCR under induc-
ing conditions. Although no deleterious growth consequences
were observed, intrinsic overexpression may complicate
pNiiA-CPR mutant construction and/or analysis in some
instances.
Despite a high concordance in A. fumigatus gene essentiality
to known essential S. cerevisiae and C. albicans orthologs,
several exceptions were observed. In some instances, this is
due to gene redundancy, as we have demonstrated by our
genetic analysis of the ERG11 gene family and may similarly
relate to ALR1. However, other nonessential phenotypes
determined for this gene set were more surprising. For
example, ERG27, although essential in both S. cerevisiae and C.
albicans, lacked a clear growth phenotype in A. fumigatus. This
phenotype cannot be attributed to the failure of the pNiiA
promoter to sufﬁciently repress ERG27 expression since we
could construct a viable ERG27 deletion mutant by gene
disruption (Table 1). As ERG27 deﬁnes the last ‘‘essential’’
step in the S. cerevisiae ergosterol biosynthetic pathway and
ergosterol intermediates that accumulate in ERG mutants are
implicated as causing the phenotypes/chemotypes resulting
from disrupting speciﬁc steps in the pathway [28], one
possibility is that the presumed ergosterol intermediate
(possibly 4-methylzymosterol or 4,4-dimethylzymosterol) is
not deleterious for A. fumigatus growth. Indeed, an extended
pNiiA-CPR analysis of the ergosterol pathway reveals that
additional genes deﬁning the last essential steps in this
pathway in S. cerevisiae (e.g., ERG26) are not essential in A.
fumigatus (W. Hu, H. Wang, S. Sillaots, S. Kauffman, J. Becker,
et al., unpublished data). Other interesting examples include
the GDP-GTP exchange factors (GEF) ROM2 and CDC24 that
regulate Rho1p and Cdc42p, respectively, in S. cerevisiae
[29,30]. Again, ROM2 was independently conﬁrmed as
nonessential in A. fumigatus as a viable knockout strain was
constructed (Table 1) despite lacking a second clear homolog
in A. fumigatus and sharing high homology (1e-155) to an
essential C. albicans ortholog. In contrast, the A. fumigatus gene
identiﬁed as sharing the greatest homology to CDC24 lacks
striking homology (7e-30) to S. cerevisiae or C. albicans CDC24
and thus may be functionally distinct from CDC24. Regard-
less, it is unexpected that two GEF proteins critical to the
process of polarized growth in yeast are either nonessential
or absent from the A. fumigatus mycelial growth process, as is
similarly the case for multiple polarized growth positional
markers (e.g., BUD3, BUD8, and BUD9) [27]. Indeed, these
examples stress the requirement for performing such analyses
directly in A. fumigatus.
Our genetic analysis of the A. fumigatus ERG11 gene family
begins to address the relative role of each ERG11 gene
member during mycelial growth, as well as issues relating to
differences in A. fumigatus activity among azole-based drugs.
We demonstrate by genetic inactivation of either homolog
that each enzyme can compensate for the lack of the other
but that inactivation of both ERG11A and ERG11B is inviable
in A. fumigatus. Therefore, azole-based antifungal drugs must
inhibit both members of the ERG11 gene family in order to
display potent inhibitory activity against A. fumigatus. This
may (in part) reﬂect the highly variable A. fumigatus MIC levels
between azole-based drugs. In addition, we demonstrate that
ERG11A mutants (rather than ERG11B mutants) are specif-
ically hypersensitive to ﬂuconazole, suggesting that ERG11A
encodes the major 14a-demethylase activity contributing to
the poor susceptibility of A. fumigatus to this drug. As ERG11A
mutant also displays hypersensitivity to itraconazole and
additional azoles [23], ERG11A may encode the major 14a-
demethylase activity required for mycelial growth. Consistent
with this view, multiple missense mutations of ERG11A
(rather than ERG11B) have been linked to itraconazole and
posoconazole resistance by UV mutagenesis studies and
analysis of azole-resistant clinical isolates of A. fumigatus
[31–33]. ERG11Ap may also possess an inherently greater
resistance to azoles, although biochemical studies are
required to address this possibility. Additional studies are
also required to address the functional role of ERG11B.
Although we demonstrate that it is not solely required for A.
fumigatus pathogenesis, it is unclear whether ERG11B serves
exclusively a redundant role with ERG11A or a more
specialized function under particular conditions.
A variety of alternative strategies (see Introduction) to
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currently being pursued, and where possible, we have
compared pNiiA-CPR terminal phenotypes to those reported
[12–15]. Recently, a doxycycline-regulated gene expression
system in A. fumigatus was reported, although it remains to be
tested using an endogenous A. fumigatus gene [16]. Unlike
previous reports, our work employs a directed strategy to
systematically evaluate A. fumigatus essential genes on a
relatively large scale and distinguish between cidal or static
growth-arrested terminal phenotypes. Importantly, the regu-
latable promoter approach circumvents the need to comple-
ment mutants with their corresponding wild-type gene; a
difﬁcult and time-consuming process in A. fumigatus. The
ability to recover multiple, independently generated, pro-
moter replacement mutants by this method also serves to
reinforce the gene-speciﬁc phenotypes observed. Unlike
alternative strategies, we demonstrate that pNiiA-CPR mu-
tants can be used to validate the gene essentiality in an
immunocompromised murine model of infection. Patho-
genesis studies assist prioritization of essential genes for drug
screening and provide a genetic prediction that cognate
inhibitors would display similar efﬁcacy in an animal model
of infection. Finally, unlike a genetic screen, this approach
allows an up-front systematic examination of speciﬁc A.
fumigatus genes that meet bioinformatic spectrum criteria
and/or essential phenotypes in other fungal organisms and,
hence, enables a rapid and focused survey of potential broad-
spectrum antifungal drug targets. In this way, we demonstrate
a signiﬁcant enrichment in the identiﬁcation and validation
of essential genes in this pathogen and envision that its utility
could be expanded.
The principal limitation to the pNiiA-CPR strategy is that,
as with any other promoter replacement strategy, it will fail to
correctly identify gene essentiality in cases where endogenous
gene expression levels are naturally lower than the residual
level achieved by repression of the NiiA promoter. Although
our data demonstrate that such limitations are not common,
we can neither rule out this complication nor predict its
occurrence among individual genes tested. In cases where a
more rigorous analysis of a single (or relatively small number
of genes) is of particular interest, an independent veriﬁcation
of the null phenotype(s) should be performed by gene
disruption, as performed in Table 1. An advantage of this
approach is that the pNiiA-CPR strategy offers a means to
identify the majority of essential genes in this pathogen.
Minor technical limitations of this approach relate to the
requirement to predict the gene’s correct start codon, which
can be particularly difﬁcult for those A. fumigatus genes that
contain extremely short 59 exons. In addition, construction of
pNiiA-CPR cassettes involves step-by-step subcloning to
introduce sufﬁcient ﬂanking homology to each given gene.
Greater throughput of cassette constructions could be
achieved using gap repair methods amenable in S. cerevisiae
[34]. Although relatively large regions of ﬂanking homology
are required to correctly target promoter replacement
cassettes, shorter ﬂanking regions could be used in con-
junction with a recipient strain deleted of Ku70 or Ku80
[35,36].
Limitations to the murine model described also exist.
Again, residual levels of expression of pNiiA-CPR mutants in
vivo may not always be sufﬁcient to produce an avirulent
phenotype. This depends not only quantitatively on the
differential level of repression achieved versus wild-type
expression but also on the qualitative level of expression
necessary to support function, which also can vary between
genes and cannot be predicted. For example, we cannot rule
out the possibility that the observed pNiiA-AUR1 virulence
(despite this gene displaying a 4þ growth phenotype) may
reﬂect an insufﬁcient shutoff within the host. Alternatively,
the pNiiA-AUR1 mutant may be suppressed in vivo by the
uptake of host sphingolipids in a manner analogous to that
reported of Candida glabrata ERG11 and ERG9 mutants (see
below) [37,38]. Notwithstanding this limitation, multiple (n ¼
5) individual pNiiA-CPR mutants could unambiguously be
conﬁrmed as avirulent by this murine model, strongly
suggesting its general utility (Figure 7B and 7C). Indeed,
although potential drug targets may be missed, others are
deﬁnitively identiﬁed, such as GFA1, which is directly
conﬁrmed as (1) essential for growth, (2) displaying a cidal
terminal phenotype, and (3) avirulent in a murine model of
pathogenesis. Although the murine model does not reﬂect a
true pulmonary aspergillosis infection model (because mice
were infected through tail vein injection rather than the
normal route of infection, namely inhalation), such improve-
ments can be envisioned. Also, unlike that of a tetracycline-
regulatable promoter system [11], virulence of pNiiA-CPR
mutants can only be evaluated from the perspective of
prophylactic antifungal drug targets because repression is
constitutive rather than controlled. Nonetheless, pNiiA-CPR
mutants provide a unique advantage over alternative meth-
ods [12,13,15] to validate A. fumigatus genes in pathogenesis
studies.
Formal demonstration that gene essentiality conﬁrmed in
vitro indeed confers an avirulent phenotype is necessary, as
exempliﬁed by phenotypic analysis of ERG11 across fungal
pathogens. Surprisingly, neither ERG11 nor ERG9 is essential
in a murine model of C. glabrata infection, despite both genes
being conﬁrmed as essential in vitro [37,38]. Instead, C.
glabrata ERG11 and ERG9 mutants are virulent in a host
environment, and it is demonstrated that they scavenge host
cholesterol to suppress ergosterol biosynthetic defects [37,38].
Direct experimentation was required to rule out that this
phenotype extends to A. fumigatus. Although neither ERG11A
nor ERG11B mutants were avirulent, the ERG11 double
mutant (erg11BD,p NiiA-ERG11A) is completely avirulent. In
the case of novel antifungal targets, one can neither predict
the consequences of their inactivation in an animal model
nor neglect their direct experimental conﬁrmation. More-
over, as A. fumigatus pathogenesis likely reﬂects its saprophytic
lifestyle and virulence factors remain to be identiﬁed, a
pNiiA-CPR strategy demonstrating avirulence of essential
genes offers a broad set of potential drug targets.
In conclusion, the pNiiA-CPR strategy overcomes a number
of historical challenges in applying molecular genetics to A.
fumigatus and is highly amenable to genetically investigate A.
fumigatus biology as well as to validate essential genes in this
important human fungal pathogen. This approach facilitates
their phenotypic analysis both in vitro and in vivo, and the
resulting conditional mutants serve as target-based whole cell
assays, thereby enabling the discovery, prioritization, and
screening of novel antifungal targets directly in A. fumigatus.
Indeed, promoter replacement strategies in C. albicans [11]
and here in A. fumigatus encourage its broader application.
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Strains, media, and cultural conditions. A. fumigatus wild-type strain
CEA10 and its uracil and uridine auxotroph, CEA17, were used in this
study [39]. ACM and AMM were prepared as reported [40]. ACM
supplemented with uracil and uridine was used to obtain CEA17
conidia suspensions and to produce mycelia for protoplast prepara-
tion. For protoplast transformation, a modiﬁed AMM was used that
contained 10 mM Mg(NO3)2 as the sole nitrogen source and 1% (w/v)
glucose as the sole carbon source (AMM plus nitrate). In addition,
AMM (AMM plus ammonium) that contained 10 mM ammonium
tartrate (C4H12N2O6; Sigma, http://www.sigmaaldrich.com) as the sole
nitrogen source was used to repress the pNiiA for phenotypic analysis
of pNiiA-CPR mutant. A. fumigatus was grown at 37 8C except where
otherwise mentioned.
Construction of plasmid pPyrG-pNiiA. Plasmid pPyrG-pNiiA was
constructed as follows (Figure 1A). Brieﬂy, the A. niger pyrG selectable
marker and the pNiiA sequence were ampliﬁed by PCR from plasmid
pAB4-ARp [41] (kindly provided by Christophe d’Enfert, Institut
Pasteur), and A. fumigatus genomic DNA, respectively, using gene-
speciﬁc primers containing multiple cloning sites (Table S1). The
above PCR products of pyrG and pNiiA were ﬁrst digested with Not1/
Nde1 and Nde1/Xho1, respectively, and then subcloned into pBlue-
script (SK; Stratagene, http://www.stratagene.com) at the Not1/Xho1
sites. The resulting plasmid is pPyrG-pNiiA, which contains pyrG-
pNiiA cassette ﬂanked on either side with a couple of cloning sites
(Figure 1A).
Construction of pNiiA-CPR cassette. Through a subcloning
strategy, CPR cassette was constructed that included the A. niger PyrG
selectable marker and the pNiiA sequence ﬂanked on either side with
approximately 1.5 kb of gene-speciﬁc ﬂanking sequence (Figure 1B).
Brieﬂy, the CPR cassette was constructed in two steps. In step 1,
approximately 1.5-kb 59-ﬂanking sequence (left arm) that was usually
250 bp upstream of the ATG start codon of the target gene was
ampliﬁed by PCR from A. fumigatus CEA10 genomic DNA with two
gene-speciﬁc primers and then subcloned into suitable cloning sites
(usually at Not1 and Mlu1) of the pyrG side of plasmid pPyrG-pNiiA.
In step 2, approximately 1.5-kb downstream (39-) genomic ﬂanking
sequence (right arm) that starts at the ATG start codon was ampliﬁed
from A. fumigatus CEA10 genomic DNA with two gene-speciﬁc
primers and then subcloned into the pNiiA side of plasmid pPyrG-
pNiiA (usually at Asc1 and Pac1 sites). The resulting pNiiA-CPR
cassette was excised from the plasmid by digesting with restriction
enzymes at either end of the cassette (usually Not1 and Pac1) and
used to transform A. fumigatus strain CEA17 (see below).
Protoplast preparation and transformation. Promoter replacement
cassette (pNiiA-CPR cassette) DNA was introduced into A. fumigatus
strain CEA17 (pyrG
 ) by protoplast transformation according to
established procedures with minor modiﬁcations [42]. Brieﬂy,
protoplasts were prepared with freshly grown mycelium using lysing
enzyme (Sigma) (0.5 g for 50 ml digestion). From 5 to 10 lg of excised
CPR-cassette DNA was used for each transformation, and the
transformants were grown at 37 8C for 3 d on AMM (AMM plus 10
mM nitrate) containing 1.2 M sorbitol as osmotic stabilizer but
lacking uridine and uracil. Three days post-transformation, trans-
formants were transferred to fresh AMM plus nitrate plates and then
subjected to genotypic and phenotypic analysis.
Genotypic analysis. A PCR strategy was used to conﬁrm double-
crossover integrated promoter replacements in mutants in which the
endogenous promoter of the target gene has been precisely replaced
with pNiiA (Figure 1B). Genomic DNA was prepared using the DNeasy
plant kit (Qiagen, http://www.qiagen.com) from transformants grown
on AMM plus nitrate and then subjected to genotypic analysis by
PCR. Three PCRs were performed, of which two mapped the
promoter replacement junctions by using two sets of primers (L1
and L2 for left-arm junction, R1 and R2 for right-arm junction), with
the third PCR using primer set L1/P to conﬁrm the presence of the
endogenous promoter in wild-type CEA10 but not in the PR mutants
(Figure 1B). pNiiA-CPR mutants that have been conﬁrmed by
genotypic analysis were subjected to monoconidial puriﬁcation, and
the resulting monoconidial isolates were reconﬁrmed by PCR as
described above.
Phenotypic analysis of CPR mutants. The phenotypes of all CPR
mutants were evaluated by comparing the growth phenotype on
inducing (AMM plus 10 mM nitrate) and repressing (AMM plus 10
mM ammonium) conditions. Typically, the terminal growth pheno-
type was observed after 36 to 40 h at 30 8C by streaking conidiospores
onto inducing and repressing media. Qualitative scores were assigned
to each of the CPR mutants to classify the severity of the terminal
growth phenotype observed. A 4þ phenotype was assigned to CPR
mutants that failed to grow in repressed media (AMM plus
ammonium). Other growth phenotypes were scored as 3.5þ (very
strong), 3þ (strong), 2þ (mild), 1þ (minor), or 0þ (no growth
phenotype) (Figure 1C).
Cidal/static phenotypic analysis. To determine the terminal cidal/
static phenotypes of A. fumigatus essential genes, 1 3 10
3 to 1 3 10
4
conidiospores were incubated in broth AMM plus 10 mM ammonium
tartrate (repressing condition) for 0 (time zero control), 24, 48, and 72
h; washed with PBS twice; and then plated onto inducing media plate
(AMM plus 10 mM nitrate) for CFU counting. A cidal phenotype was
assigned to those genes whose conditional mutant displayed a
signiﬁcant CFU reduction (greater than 90%) after 24 h under
repressing conditions. Slow cidal targets are those that displayed
reduced cell viability after 48 or 72 h, respectively.
Immunocompromised murine model of systemic infection. A.
fumigatus strains were tested for virulence in an immunocompromised
murine model for systemic infection using CD-1 male mice (22 to 25
g; Charles River Laboratories, http://www.criver.com). Mice were
housed ﬁve per cage with food and water supplied ad libitum. All
experiments were performed according to the National Institutes of
Health guidelines for the ethical treatment of animals. Mice were
rendered immunocompromised by treatment with cyclophospha-
mide at 150 mg/kg 4 d and 1 d prior to infection and 100 mg/kg twice
a week after infection. A. fumigatus conidial suspensions were
prepared from 4- to 5-d-old cultures grown on solid medium by
harvesting the conidia with gentle shaking by hand using 5 ml of PBS,
0.2% Tween-20, and 3 ml of glass beads. The conidial suspension was
centrifuged (3,000g, 5 min), the pellet was resuspended in 0.01%
Tween-20, and the conidia were counted on a hemacytometer.
Immunocompromised mice were infected by tail vein injection of 0.1
ml of a conidial suspension of 1310
6 conidia/ml. After injection, the
conidia suspensions were diluted and plated to determine the viable
count of the inoculum. Mice were monitored three times daily for
signs of infection, up to 12 to 22 d. Animals were considered
moribund when they could no longer reach food or water. Moribund
mice, along with those surviving to the end of the experiment, were
killed by anesthetization followed by cervical dislocation. All tested
CPR mutants were coded so that laboratory workers did not know the
identity of the strains. For each strain, ﬁve mice were infected.
Essential gene validation by ORF disruption. To disrupt the
complete ORF of a target gene, a disruption cassette was constructed.
Brieﬂy, 59-ﬂanking sequence (approximately 1.5 kb, upstream of the
ATG start codon) of the target gene was ampliﬁed by PCR using two
gene-speciﬁc primers and then subcloned into the Not1/Mlu1 sites of
plasmid pPyrG-pNiiA (Figure 1A). Similarly, the 39-ﬂanking sequence
(approximately 1.5 kb, downstream of the stop codon) was ampliﬁed
by PCR and subsequently subcloned into the Nde1/Pac sites of
plasmid pPyrG-pNiiA. The resulting plasmid was digested using Not1/
Pac1 and then introduced into CEA17 strain by protoplast trans-
formation (see above). Transformants were incubated on ACM
without uracil and uridine and then subjected to genotypic analysis
by PCR using primer sets to verify the disruption junctions and ORF
disruption. Gene essentiality was inferred if no genotype-conﬁrmed
transformants could be recovered from a large population of
transformants (n . 80). Otherwise, if genotype-conﬁrmed trans-
formants were recovered, the target gene was deﬁned as nonessential.
ERG11 double knockout. To validate the gene essentiality of the
ERG11A/ERG11B gene family, a double knockout mutant was
constructed as follows. In step 1, an ERG11B null mutant (erg11BD)
was constructed by disruption of the whole ERG11B ORF using a
pyrG-based gene disruption cassette as described above. In step 2, the
pyrG selection marker was recycled from erg11BD to facilitate the
promoter replacement of ERG11A. To achieve this, the ERG11B gene
disruption plasmid was digested with Mlu1 and Asc1 to remove the
PyrG-pNiiA insert from the cassette and religated (Mlu1 and Asc1
provide compatible 59 overhangs) prior to subsequent transformation
with Escherichia coli. The resulting plasmid was then puriﬁed and
digested with Not1 and Pac1 to excise the ERG11B insert (comprising
fused 59 and 39 ﬂanking sequences and no intervening pyrG-pNiiA
insert) and used to transform erg11BD. Transformants were grown at
30 8C for 48 h on ACM containing 5 mM uridine and uricine,
respectively. The conidiospores of resulting transformants were
collected and then plated onto AMM plates containing 10 mM
nitrate and 1 mg/ml 5-FOA to counterselect pyrG
  strains. The
resulting pyrG
  strain was then genotyped by PCR to conﬁrm that the
pyrG
  selectable marker has been removed from erg11BD. In step 3,
the resulting pyrG
 , erg11BD strain was then used as the starting strain
to perform promoter replacement of ERG11A as described above.
Construction of TUB1 tandem duplicate mutant. To construct
TUB1 tandem duplicate mutants, TUB1 ORF plus approximately 1 kb
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ampliﬁed by PCR and then subcloned into the Asc1 and Pac1 sites of
plasmid pPyrG-pNiiA (Figure 1A). The resulting plasmid was used to
transform A. fumigatus CEA17 by protoplast transformation as
described above. Transformants were incubated on AMM plus nitrate
without uracil and uridine and then subjected to genotypic analysis
by PCR using primer sets to verify single crossover event.
RT-PCR and real-time RT-PCR. To perform RT-PCR, pNiiA-CPR
mutants and wild-type were grown either in AMM plus nitrate
(inducing) or in AMM plus ammonium (repressing) at 37 8C for 20 h.
Total RNA was extracted using the RNeasy plant mini kit (Qiagen)
according to the manufacturer’s instructions. Total RNA samples
were treated with Turbo-DNase I at 37 8C for 30 to 40 min according
to the manufacturer’s manual (Ambion, http://www.ambion.com).
RNA samples obtained using these procedures lacked detectable
genomic DNA as assayed by control PCR tests. The ﬁrst-strand cDNA
was synthesized by using ThermoScript RT-PCR system and oligo(dT)
primers (Invitrogen, http://www.invitrogen.com) according to the
manufacturer’s instructions. Double-strand cDNAs were then ampli-
ﬁed from the above ﬁrst-strand cDNA by PCR using a set of gene-
speciﬁc forward and reverse primers (Table S1). A typical PCR
program is as the following: 94 8C for 2 min, 1 cycle; 94 8C for 30 s, 60
8C for 30 s and 72 8C for 2 min, 16 to 20 cycles; and then extension at
72 8C for 10 min. PCR products were then subject to 1% agarose-gel
analysis.
To perform real-time RT-PCR, total RNA samples was extracted
and treated with Turbo-DNase (Ambion), and the ﬁrst-strand cDNA
was synthesized as described above. Real-time PCR was then
performed using the ABI 7500 thermocycler (Applied Biosystems,
http://www.appliedbiosystems.com). Reactions containing cDNA, for-
ward and reverse primers, and a ﬂuorescent probe (integrated DNA
technologies, invasive aspergillosis, and applied biosystems; see Table
S2) and TaqMan Master Mix were run in triplicate using the standard
conditions suggested by the manufacturer. When possible, primers
and probes were speciﬁcally designed to cross adjacent exons to avoid
ampliﬁcation of trace genomic DNA. The mean threshold cycle value
(Ct) for each sample was used to calculate cDNA abundance under
inducing or repressing growth conditions, and samples were
normalized based on total input RNA as previously described [43].
Changes in expression were calculated relative to the Ct for each gene
expressed by a wild-type strain.
Northern blot analysis. Northern blot analysis was carried out
according to established procedures [14,15]. Brieﬂy, total fungal RNA
was prepared using the RNeasy plant mini kit (Qiagen) according to
the manufacturer’s instructions. From 5 to 10 lg of total RNA was
used for each sample. P
32-labeled ALR1 and ACT1 probes were made
from PCR products ampliﬁed using gene-speciﬁc primers (Table S1).
Drug susceptibility testing. MIC testing of antifungal drugs against
A. fumigatus wild-type strain CEA10 and conditional mutants
constructed from promoter replacement was performed by broth
microdilution as described by the National Committee for Clinical
Laboratory Standards with minor modiﬁcations [44]. The A. fumigatus
inoculum was adjusted to concentrations of approximately 2 3 10
3
conidiospores/ml in AMM, and an aliquot of 0.1 ml was added to
microtiter wells containing 0.1 ml of antifungal drug solutions in
AMM. For inducing conditions, AMM plus 10 mM Mg(NO3)2 was used.
To sensitize the CPR mutants, ammonium tartrate was added to AMM
plus 10 mM nitrate at a ﬁnal concentration of 10 to 160 lM. The
microtiter plate was incubated at 37 8C for 48 h, and the MICs were
determined as the lowest concentration that completely inhibited
mycelia growth.
Supporting Information
Figure S1. Microscopic Analysis of pNiiA-nudC Terminal phenotypes
(A) Phase contrast microscopy (3160) demonstrates normal hyphal
growth of pNiiA-nudC mutants incubated under inducing conditions
(16 h at 30 8C).
(B) Phase contrast microscopy demonstrates pNiiA-nudC conidia
typically failed to germinate (greater than 70%) and a minority (less
than 30%) formed short growth-arrested germ tubes when incubated
under repressing conditions (16 h at 30 8C).
(C and D) Higher magniﬁcation (3400) phase contrast microscopy
and DAPI staining of pNiiA-nudC mutant incubated under the same
conditions as above.
(E and F) DAPI staining demonstrates a nuclear distribution
phenotype of the pNiiA-nudC mutant as multiple nuclei remain
inside the ungerminated conidia and short growth-arrested germ
tubes under repressing conditions (F) but not in mycelia under
inducing conditions (E).
Found at doi:10.1371/journal.ppat.0030024.sg001 (5.3 MB PPT).
Figure S2. RT-PCR Analysis of Expression Level of Multiple pNiiA-
CPR Mutants
pNiiA-CPR mutants were grown in AMM plus nitrate (In) or AMM
plus ammonium (Re) at 37 8C for 20 h, and total RNA was extracted
and normalized. To monitor and ensure even sample loading, RT-
PCRs for the ACT1 transcript were also performed using identical
samples (unpublished data). Standard PCR was also performed to
conﬁrm that there is no detectable genomic-DNA contamination
(unpublished data).
Found at doi:10.1371/journal.ppat.0030024.sg002 (197 KB PPT).
Figure S3. Normal Hyphal Growth of pNiiA-CPR Mutants under
Inducing Conditions
To compare terminal phenotypes characterized in Figure 4, pNiiA-
CPR mutants of GFA1, TUB1, SEC31, SLY1, ERG10, HEM15, PRI1, and
FKS1 were grown on AMM plus nitrate (inducing conditions) at 30 8C
for 2 d. Micrographs were taken under a microscope at a
magniﬁcation of approximately 380.
Found at doi:10.1371/journal.ppat.0030024.sg003 (299 KB PPT).
Table S1. Primers Used for pNiiA Cassette Construction, Northern
Blot, and RT-PCR
Found at doi:10.1371/journal.ppat.0030024.st001 (35 KB DOC).
Table S2. Forward and Reverse Primers and Probes Used in Real-
Time RT-PCR
Found at doi:10.1371/journal.ppat.0030024.st002 (26 KB DOC).
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